Eur J Clin Invest. 2021 May 27:e13624. doi: 10.1111/eci.13624. Online ahead of print.
Over the last years, several trials offered new evidence on heart failure (HF) treatment. For HF with reduced left ventricular ejection fraction, type 2 sodium-glucose cotransporter inhibitors, aside from sacubitril-valsartan, demonstrated extraordinary efficacy in ameliorating patients' prognosis. Some new molecules (e.g. vericiguat, omecamtiv mecarbil and ferric carboxymaltose) correct iron deficiency and have shown to be capable of furthering reducing the burden of HF hospitalisation.